Compare AbbVie Inc (ABBV) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? AbbVie Inc trades at $253.68 (market cap $449.91B), while Vanguard Total Stock Market Index Fund ETF trades at $367.5. The key difference: AbbVie Inc pays a 2.72% dividend while Vanguard Total Stock Market Index Fund ETF pays none. Which is the better fit depends on your goals.
| ABBV | VTI | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $374.36 |
52-Week Low | $184.85 | $305.58 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
VTI trades at $371.67, up 0.79% today, with a bullish technical outlook supported by moving averages. The ETF offers broad U.S. equity exposure across 3,400+ stocks with a minimal 0.03% expense ratio. Recent news highlights its inclusion in new Trump Accounts and comparisons with competing total market ETFs, reinforcing its popularity for long-term wealth building.
VTI presents a low-cost core holding for diversified U.S. stock exposure, though its neutral oscillators and elevated short-term RSI suggest near-term consolidation risks. Market volatility and economic shifts remain key headwinds, but analyst sentiment favors its long-term growth potential amid accelerating small-cap earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
